Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for Epstein-Barr virus-associated carcinoma has been reported in the published literature.
No clinical trials have been registered for Epstein-Barr virus-associated carcinoma.
4 publications have been identified in PubMed for Epstein-Barr virus-associated carcinoma. Research spans Case Report / Case Series (50%), Other (25%), and Diagnostic / Biomarker (25%).
Koriyama C (2026). [PMID: 41928280](https://pubmed.ncbi.nlm.nih.gov/41928280/). *Infect Agent Cancer*. [Diagnostic / Biomarker]
Hao L (2026). [PMID: 40734203](https://pubmed.ncbi.nlm.nih.gov/40734203/). *Clin Nucl Med*. [Case Report / Case Series]
Tao JJ (2025). [PMID: 41323060](https://pubmed.ncbi.nlm.nih.gov/41323060/). *Case Rep Oncol*. [Case Report / Case Series]
Rickard JA (2025). [PMID: 39467732](https://pubmed.ncbi.nlm.nih.gov/39467732/). *Pathology*. [Other]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:50 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Epstein-Barr virus-associated carcinoma
AI-curated news mentioning Epstein-Barr virus-associated carcinoma
Updated Jul 28, 2026
A new study discusses postoperative adjuvant treatment decisions for early Epstein-Barr virus-associated gastric cancer. This research may influence treatment protocols and improve patient outcomes in this specific cancer type.
A case report highlights the successful management of suspected Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a patient with BRAF-mutant cholangiocarcinoma. The treatment involved immune checkpoint inhibitors and BRAF/MEK inhibitors, showcasing potential therapeutic strategies for this rare condition.
A case study highlights the diagnostic and therapeutic challenges of an Epstein-Barr virus (EBV)-associated smooth muscle tumor in a patient with HIV. This research underscores the complexities of managing rare tumors linked to viral infections in immunocompromised individuals.